Sycona shares rise on positive gene therapy trial results
Beacon Therapeutics, a Syncona portfolio company, is developing laru-zova for XLRP (inherited retinal disease). The stock jumped after positive drug trial results were reported.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.